Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

 

Adams ER et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Research 2020 10.12688/wellcomeopenres.15927.1

 

Dayarathna S et al. Similarities and differences between the 'cytokine storms' in acute dengue and COVID-19 Sci Rep. 10(1):19839. 2020. 10.1038/s41598-020-76836-2

 

Drake TM et al. Outcome of hospitalization for COVID-19 in patients with Interstitial Lung Disease: An international multicenter study. In press Am J Resp Crit Care Med 2020 10.1164/rccm.202007-2794OC

 

 Eyre DW et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife 9:e60675 2020.  DOI: 10.7554/eLife.60675

 

 Halifax R et al. Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single centre high dependency unit experience. BMJ Open Respir Res 7:e000678. 2020. 10.1136/bmjresp-2020-000678

 

 Huang K-Y A et al. Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans. BioRxiv 2020 10.1101/2020.08.28.267526

 

 Huo J et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe 28 p445-454.e6  2020. 10.1016/j.chom.2020.06.010

 

Huo J et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 27, 846–854 2020. 10.1038/s41594-020-0469-6

 

James PT et al. Could nutrition modulate COVID-19 susceptibility and severity of disease? A systematic review. MedRxiv 2020 10.1101/2020.10.19.20214395

 

Koohy H et al. Potential CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains. Front Immunol 2020 11:579480. 10.3389/fimmu.2020.579480

 

 Lee CH et al. In Silico identification of vaccine targets for 2019-nCoV. F1000Res  9: 145. 2020. 10.12688/f1000research.22507.2

 

 Lumley SF et al. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Euro Surveill  25(42):pii=2001721. 2020.  10.2807/1560-7917.ES.2020.25.41.2001721

 

 Malavige G et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. In press Sci Rep 2020

 

 Mann E et al. Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis. Sci Immunol 5, eabd6197 2020. DOI: 10.1126/sciimmunol.abd6197

 

Miao X et al. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs 12 p1, 2020. 10.1080/19420862.2020.1804241

 

Monk P et al. Safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med S2213-2600(20)30511-7. 2020.  10.1016/S2213-2600(20)30511-7.

 

 National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 12, P1390-1400 2020. 10.1016/S1473-3099(20)30634-4

 

Ogbe A et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. MedRxiv 2020 10.1101/2020.09.28.20202929v1

 

Olagnier D et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun 11, 4938. 2020. 10.1038/s41467-020-18764-3

 

Peng Y et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020 21, p1336–1345 10.1038/s41590-020-0782-6

 

Raman B et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. In press Lancet EClin Med 2020

 

Rehwinkel J et al. cGAMP loading enhances the immunogenicity of VLP vaccines. In press EMBO Mol Med 2020

 

Shah A et al. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19. Crit Care 24, 320. 2020. 10.1186/s13054-020-03051-w

 

Song R et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. J Infect 81(2): e26–e30. 2020. 10.1016/j.jinf.2020.04.018

 

Tan TK et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody response. In press Nat Commun 2020 10.1101/2020.08.31.275701 (preprint)

 

Townsend A et al. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. MedRxiv 2020 10.1101/2020.10.02.20205831

 

Townsend A. Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19. Med Hypotheses 144 110043 2020. 10.1016/j.mehy.2020.110043

 

Wilkinson T et al. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials 21(1):691. 2020. 10.1186/s13063-020-04584-9.

 

Wurm H et al. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler 26: 1261-1264 2020. 10.1177/1352458520943791

 

Zhang C et al. A Novel Scoring System for Prediction of Disease Severity in COVID-19. Front Cell Infect Microbiol 10, p318 2020. 10.3389/fcimb.2020.00318

 

Zhang Y et al.  Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. J Infect Dis 222, p 34–37, 2020. 10.1093/infdis/jiaa224

 

Zhao Y et al. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease. JCI Insight 5(13):e139834. 2020. 10.1172/jci.insight.139834.

 

Zhou D et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27, 950–958. 2020. 10.1038/s41594-020-0480-y